| 摘要 |
Disclosed is the use of a compound targeting ApoCIII in the manufacture of a medicament for increasing HDL levels and/or improving the ratio of TG to HDL in an animal thereby increasing chylomicron clearance in an animal; wherein the compound comprises a modified oligonucleotide comprising or consisting of the sequence of SEQ ID NO: 3 and wherein the compound is capable of inhibiting apolipoprotein C-III. Further disclosed is the use of a compound comprising a modified oligonucleotide targeting ApoCIII comprising or consisting of SEQ ID NO: 3, wherein the modified oligonucleotide comprises: (a) a gap segment consisting of 10 linked deoxynucleosides; (b) a 5’ wing segment consisting of 5 linked nucleosides; (c) a 3’ wing segment consisting 5 linked nucleosides; wherein the gap segment is positioned immediately adjacent to and between the 5’ wing segment and the 3’ wing segment, wherein each nucleoside of each wing segment comprises a 2’-O-methoxyethyl sugar, wherein each cytosine is a 5-methylcytosine, and wherein each internucleoside linkage is a phosphorothioate linkage; and wherein the modified oligonucleotide is capable of inhibiting the expression of apolipoprotein C-III; in the manufacture of a medicament for increasing HDL levels and/or improving the ratio of TG to HDL in an animal thereby increasing chylomicron clearance in an animal. |
